The ongoing novel coronavirus (COVID-19) pandemic has highlighted the need for individuals to have easy access to healthcare facilities for treatment as well as vaccinations. The surge in COVID-19 hospitalizations during 2020 also underscored the fact that accessibility to nearby hospitals for testing, treatment and vaccination sites is crucial for patients with fever or respiratory symptoms. Although necessary, quantifying healthcare access is challenging as it depends on a complex interaction between underlying socioeconomic and physical factors.
Health care providers and technology companies may consider forming health equity advisory algorithmic stewardship committees that can provide oversight and evaluate the design and implementation of real-world AI/ML solutions.
Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 223-242
This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods
Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 17-39
This book chapter advances SDG #3 and #10 by presenting drug delivery systems based on nanotechnology to treat Alzheimer’s disease.
Average age at death is younger for intellectual and developmental disabled adults. This disparity is more pronounced among all racial-ethnic minorities. Racial-ethnic inequities are most severe among adults with cerebral palsy.
The paper presents policy responses to the pandemic that illustrate how the crisis has opened opportunities for initiating changes that can lead to a more just food system.
Mental health condition diagnoses were associated with other underlying chronic health conditions and a modestly increased risk of a range of adverse outcomes. The findings suggested that mental health conditions are an important risk factor in adverse maternal outcomes.
This papers demonstrates how simple substitutions can be made in individuals’ diets to substantially reduce their carbon and water scarcity footprints without sacrificing dietary quality. Such substitutions may be easier to promote than complex dietary patterns.
Background: Among patients with type 2 diabetes, minority racial/ethnic groups have a higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia. These groups may especially benefit from newer diabetes medication classes, but high cost may limit access. We examined the association of race/ethnicity with the initiation of newer diabetes medications (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors).
Looks at disparities in access to healthcare among Indigenous people.
